Sipuleucel-T (APC8015) for prostate cancer.
Sipuleucel-T (Provenge; APC8015; Dendreon Corp, WA, USA) is a novel immunotherapeutic cellular product, which includes autologous dendritic cells pulsed ex vivo with a recombinant fusion protein (PA2024) consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase. Two Phase II trials in men with androgen-dependent biochemically relapsed prostate cancer have demonstrated a decrease in prostate-specific antigen and prolongation in prostate-specific antigen doubling time. In men with hormone-refractory prostate cancer, clinical trials have demonstrated both biological activity and clinical response to sipuleucel-T. Data from two Phase III trials in men with asymptomatic, metastatic hormone-refractory prostate cancer demonstrated an improved median overall survival in men who received sipuleucel-T compared with placebo. Clinical trials are ongoing or are being developed to evaluate sipuleucel-T in various prostate cancer disease states and in combination with other treatment modalities.
So-Rosillo
Rosendo
R
Hematology/Oncology, University of California, 505 Parnassus Avenue, M1286 San Francisco, CA 94143-1270, USA. rsorosillo@hemeonc.ucsf.edu
Small
Eric J
EJ
D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D014020:Tissue Extracts / Q000627:therapeutic use*
D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T